Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „formulation“
Suchtreffer
Begriffe & Kennungen
Lumigan · 4.8 · Table 2 List of adverse reactions with LUMIGAN 0.3 mg/ml (multi-dose formulation)
Eintrag öffnenLysodren · 4.5 · Fat-rich food: Data with various mitotane formulations suggest that administration with fat-rich food enhances
Eintrag öffnenM-M-RVaxPro · 4.5 · Published clinical data support concomitant administration of the previous formulation of the measles, mumps a
Eintrag öffnenMabThera · 4.8 · Adverse reactions reported in MabThera intravenous formulation usage
Eintrag öffnenMabThera · 4.8 · Adverse reactions reported in MabThera intravenous formulation usage
Eintrag öffnenMabThera · 4.8 · Adverse reactions reported in MabThera subcutaneous formulation usage
Eintrag öffnenMabThera · 4.8 · Adverse reactions reported in MabThera subcutaneous formulation usage
Eintrag öffnenMabThera · 4.8 · During the development programme, the safety profile of MabThera subcutaneous formulation was comparable to th
Eintrag öffnenMabThera · 4.8 · During the development programme, the safety profile of MabThera subcutaneous formulation was comparable to th
Eintrag öffnenMabThera · 4.8 · The risk of acute administration-related reactions associated with the subcutaneous formulation of MabThera wa
Eintrag öffnenMabThera · 4.8 · The risk of acute administration-related reactions associated with the subcutaneous formulation of MabThera wa
Eintrag öffnenMissbrauch-abschreckende Formulierungen
Eintrag öffnenNeoclarityn · 4.8 · In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total
Eintrag öffnenNoxafil · 4.5 · The following information was derived from data with posaconazole oral suspension or early tablet formulation.
Eintrag öffnenOpdivo · 4.8 · 175 Infusion reactions (intravenous formulation) In patients treated with nivolumab monotherapy, the incidence
Eintrag öffnenOpdivo · 4.8 · In the dataset of nivolumab intravenous formulation 240 mg every 2 weeks in combination with cabozantinib 40 m
Eintrag öffnenOpdivo · 4.8 · Intravenous formulation
Eintrag öffnenOpdivo · 4.8 · Subcutaneous formulation
Eintrag öffnenProcysbi · 4.8 · For the immediate-release formulation of cysteamine bitartrate, approximately 35% of patients can be expected
Eintrag öffnenRemsima · 4.8 · Intravenous formulation
Eintrag öffnen